PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Staab-Weijnitz, C.A. ; Hilgendorff, A.*

Inhibition of epithelial cell YAP-TEAD/LOX signaling attenuates pulmonary fibrosis.

(2024)
Verlagsversion
Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal disease characterized by excessive extracellular matrix (ECM) deposition. Current IPF therapies slow disease progression but do not stop or reverse it. The (myo)fibroblasts are thought to be the main cellular contributors to excessive ECM production in IPF. Here we report that fibrotic AT2 cells regulate production and crosslinking of ECM via the co-transcriptional activator YAP. YAP leads to increase expression of Lysyloxidase (LOX) and subsequent LOX mediated crosslinking by fibrotic AT2 cells. Pharmacological YAP inhibition reverses fibrotic AT2 cell reprogramming and LOX expression in experimental lung fibrosis in vivo and in human fibrotic tissue ex vivo. We thus identify YAP-TEAD/LOX inhibition in AT2 cells as a promising potential new therapy for IPF patients.
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Forschungsdaten
Schlagwörter lung fibrosis; precision cut lung slices; RNA-Seq ; Lung; Verteporfin/therapeutic use ; Precision Medicine
Sprache englisch
Veröffentlichungsjahr 2024
HGF-Berichtsjahr 2024
Anmeldeland DE
Institut(e) Institute of Lung Health and Immunity (LHI)
POF Topic(s) 80000 - German Center for Lung Research
Forschungsfeld(er) Lung Research
PSP-Element(e) G-501800-817
Erfassungsdatum 2025-03-11
[➜Korrektur melden]